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Abstract
Hsp90 is a promising therapeutic target for the treatment of cancer. Novobiocin is the first Hsp90
C-terminal inhibitor ever identified and recent structure-activity relationship studies on the
noviose sugar identified several commercially available amines as suitable surrogates. In an effort
to further understand this region of the molecule, analogues containing various N′-amino
substituents were prepared and evaluated against two breast cancer cell lines for determination of
their efficacy. Compound 37j manifested the most potent anti-proliferative activity from these
studies and induced Hsp90-dependent client protein degradation at mid nano-molar
concentrations.
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The 90 kDa heat shock protein is an ATP-dependent chaperone that belongs to the GHKL
superfamily.1 It is one of the most abundant molecular chaperones in the cytosol and
promotes the folding, activation and stabilization of more than 200 client proteins,
approximately 50 of which are directly associated with cell growth and/or signaling
pathways.2 Malignant or mutated oncogenic proteins, such as Her-2, Raf-1, Akt, CDK4, Src,
Flt-3, hTert, c-Met, etc, are distributed amongst the six hallmarks of cancer and are highly
dependent upon the Hsp90 protein folding machinery for their ability to promote cell
survival, proliferation, and adaptation.3 In contrast to the homodimeric chaperone that is
present in normal cells, Hsp90 exists as a heteroprotein super-chaperone complex in cancer
cells and is bound to oncogenic proteins that are sensitive to physiological stress.4 In such
scenarios, Hsp90 inhibition results in the simultaneous disruption of multiple oncogenic
pathways and eventually leads to cancer cell death, while largely sparing normal cells. As a
consequence, Hsp90 has emerged as a promising therapeutic target for the treatment of
cancer.
Hsp90 contains three highly conserved domains: the 25 kDa N-terminus is responsible for
ATPase activity, the 35 kDa middle domain is utilized for substrate recognition, and the 12
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kDa C-terminus elicits dimerization and co-chaperone binding.5 The N-terminal domain has
been extensively studied and 16 small molecules targeting this region have been evaluated in
clinical trials.6,7 However, detriments such as heat shock induction and cytostatic activity
associated with N-terminal inhibition has limited their potential use against cancer.8
However, some small molecules that bind to the C-terminal domain do not induce the pro-
survival heat shock response, and in some cases, even cause Hsp70 and Hsp90
degradation.9–12 Because the Hsp90 C-terminus is responsible for mediating interactions
with co-chaperones such as HOP (Hsp70-Hsp90 organization protein) and the
immunophilins (eg. FK506 binding protein) to facilitate client protein maturation,13,14 small
molecule modulation of this region exhibits activities not observed with N-terminal
inhibitors.11,15
Novobiocin was first identified as an Hsp90 C-terminal inhibitor in 2000 by Neckers and
coworkers.16 Subsequent modification to novobiocin has led to the elucidation of structure-
activity relationships and analogues that exhibit superior inhibitory activity.17–21 Deletion of
both the 4-hydroxy substituent on the coumarin ring and the 3′-carbamoyl group on noviose
resulted in DHN2, which transformed novobiocin from a DNA gyrase inhibitor to a
selective Hsp90 inhibitor (Figure 1).22 Subsequent replacement of the synthetically complex
noviose sugar with readily available amines led to molecules represented by NA-1
(novobiocin analogue 1, Figure 1) and NA-2 (novobiocin analogue 2) that manifest
increased anti-proliferative activity and solubility.21 During the course of studies aimed at
the modification of these amines, Huang and coworkers developed a three-dimensional
quantitative structure-activity relationship (3D-QSAR) model that suggested modifications
to the amine may improve anti-proliferative activity.23 Consequently, second generation
amino-analogues were designed, synthesized and evaluated against two breast cancer cell
lines.
SAR generated from novobiocin analogues suggested that a three-carbon linker between the
7-coumarin phenol and the amine was optimal.21 Although the anti-proliferative activity of
NA-1 and NA-2 suggested flexibility of the amine moiety may be required, increasing the
number of rotatable bonds is generally considered detrimental, due to entropic penalties.
Therefore, novobiocin analogues containing rigid heterocyclic piperidine and pyrroridine
derivatives were synthesized and evaluated. As illustrated in Figure 2, the piperidine or
pyrrolidine ring system was linked to the 7-phenolic oxygen by 1–3 carbons.
These amines were assembled with the coumarin core in modular fashion utilizing Boc-
protected secondary amines (1 and 3) or tertiary amines (2 and 4), which underwent
Mitsunobu esterification with phenol 5 to afford 6–9.21 Subsequent hydrogenolysis to
unmask the amine allowed for amide coupling with 4-(chlorocarbonyl)-2-(3-methylbut-2-
en-1-yl)phenyl acetate (10) in the presence of pyridine afforded novobiocin C-linked
heterocyclic analogues 11–14. Acid-catalyzed deprotection of 11 and 13 resulted in
secondary amines 15 and 16. Finally, hydrolysis of ester 12 and 14–16 generated phenols
17–20 (Scheme 1).
Along with the C-linked heterocyclic derivatives (12, 14, 15–20), N-linked heterocycles
(29–33) were also synthesized (Scheme 2). Compound 23 was regarded as a versatile
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intermediate and was prepared in 3 steps. Benzyl (7-hydroxy-8-methyl-2-oxo-2H-
chromen-3-yl)carbamate (5) was treated with ten equivalents of 1,3-dibromopropane (21) in
the presence of potassium carbonate to afford alkyl bromide 22. Subsequent hydrogenolysis
followed by amide coupling with acid chloride 10 produced the corresponding amide 23.
Displacement of the bromide in 23 with amines 24–28 in N,N-dimethylformamide and
simultaneous hydrolysis of the phenolic ester gave amines 29–33.
Upon construction of the C- and N-linked heterocyclic novobiocin analogues, these
molecules were evaluated for anti-proliferative activity against SKBr3 (estrogen receptor
negative, Her2 over-expressing breast cancer cells) and MCF-7 (estrogen receptor positive
breast cancer cells) cell lines. As shown in Table 1, the anti-proliferative activities
manifested by C-linked heterocyclic analogues (12–20) were similar to NA-1, suggesting
that various ring structures are accommodated within the binding site. Interestingly, the
secondary amino analogues exhibit greater inhibitory activity than the corresponding tertiary
amines (16 vs 12, 19 vs 18), which is further exacerbated against the MCF-7 cell line.
Although piperizine analogues (29 and 30) maintained activity comparable to NA-1,
compounds 31 and 32 were inactive at the highest concentration tested. However, shrinking
the ring size to five atoms (33) restored activity, suggesting that hydrophobicity is limited in
this region and that the inclusion of heteroatoms is necessary for further extension.
Data from the first set of compounds suggest there is limited hydrophobic space, however,
further extension is possible, but requires an H-bond donor (e.g., 30), which cannot be
replaced with a hydrophobic moiety (32) or an H-bond acceptor (31). In addition, Huang
and co-workers suggested in their 3D-QSAR study that steric bulk N-substitution of NA-2
could lead to increased anti-proliferative activity.23 Therefore, analogues containing various
linear and branched N-substitutions were pursued in an effort to maintain both the
hydrophobicity and the H-bond donor properties. As shown in Scheme 3, compound 23 was
treated with primary and secondary amines (34a–34o) to produce the corresponding
secondary and tertiary amine derivatives containing various linear or branched chains (35a–
35k). Similarly, treatment of 23 with amines 34l–34o afforded compounds 35j–35o that
contain various H-bond properties to further verify whether H-bond donors or acceptors
were favored.
Anti-proliferative activity manifested by these analogues was evaluated against SKBr3 and
MCF-7 cell lines as previously described. As shown in Table 2, a bulky group (up to 3 linear
carbons, 35a, 35b, 35d, and 35f–35k except 35i) was generally well-tolerated in the binding
site. It appears as though this hydrophobic chain can be linear (35a, 35b, and 35d) or
branched (35f–35h, 35j and 35k). The diethylamine (35c) and diisopropylamine (35i)
analogues exhibited decreased anti-proliferative activity against SKBr3 cells, while the
diisopropylamine analogue manifested no activity (35e), indicating a limited amount of
space is available. Glycine ester analogue 35l and amide analogue 35n exhibited decreased
anti-proliferative activity against SKBr3 cells or MCF-7 cells while alcohol 35o retained
activity against both cancer cell lines, supporting further extension into the binding site
requires hydrogen bond donors. The significantly decreased activity of glycine acid
analogue 35m may result from limited cell membrane penetration.
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Although none of the first two sets of compounds showed significantly improved anti-
proliferative activity, it is clear that steric bulk is tolerated in the binding site. Therefore, a
set of NA-2 derivatives containing various rings (37a–37j) were prepared in a similar
synthetic sequence, as described in Scheme 4.
The anti-proliferative data (Table 3) shows that cyclohexyl (37a and 37b), benzyl (37e),
substituted benzyl (37f and 37g), and bicyclic alkyls (37i and 37j) are tolerated in the
binding site. Aniline-containing analogues were inactive (37c and 37d), possibly due to the
altered hydrogen bonding property manifested by amine due to the incorporation of the
phenyl ring. Compound 37j, which contained an N-adamantyl substitution, manifested the
most potent anti-proliferative activity against both SKBr3 and MCF-7 breast cancer cell
lines, indicating that significant space is available, but the molecule must contain a free H-
bond donor in the form of a secondary amine. In addition, 37j exhibited lower activity
against normal cells (MRC5, 5.42 μM; HMLE, 15.05 μM), thus provide a considerable
therapeutic window for the treatment of cancer.
To confirm these novobiocin analogues that contain amino groups in lieu of noviose
manifest inhibitory activity through Hsp90 inhibition, western blot analyses of cell lysates
following the administration of most active compound, 37j, were performed. As shown in
Figure 3, the Hsp90-dependent client proteins, Raf and Akt, were degraded in MCF-7 cells
in a concentration-dependent manner upon treatment with 37j. The non-Hsp90-dependent
protein, actin, was not degraded upon the administration of 37j, indicating selective
degradation of Hsp90-dependent proteins. In accordance with previous studies, Hsp90 levels
remained constant at all concentrations tested, demonstrating that 37j does not induce the
pro-survival heat shock response.
In conclusion, a library of novobiocin analogues containing a second generation of amino-
appendages was designed, synthesized and evaluated. The results showed that a variety of
bulky N-alkyl groups are well tolerated and can lead to compounds with efficacious activity
against breast cancer cells. Compound 37j, a secondary amino derivative containing an N-
adamatyl group, manifested the most potent anti-proliferative activity, which through
western blot analyses confirmed this compound inhibits the Hsp90 protein folding
machinery.
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Evolution of novobiocin analogues.
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Proposed cyclic amino derivatives of novobiocin
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Western blot analyses of MCF-7 cell lysates for Hsp90 client protein degradation after 24 h
incubation. Concentrations (in μM) of 37j are indicated above each lane. Geldanamycin (G,
500 nM) and DMSO (D) were employed respectively as positive and negative controls.
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Synthesis of C-linked heterocyclic derivatives of novobiocin
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Synthesis of terminal cycloamine derivatives of novobiocin
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Synthesis of NA-2 analogues with linear and branched chains.
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Synthesis of NA-2 derivatives with cyclic N-substitutions
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Table 1
Anti-proliferative activities NA-1 analogues.
R R′ SKBr3 (μM) MCF-7 (μM)
KU-398 H 0.76±0.17a 1.09±0.10
12 OAc 0.74±0.01 1.65±0.11
14 OAc 0.88±0.09 1.88±0.45
15 OAc 0.64±0.06 0.71±0.03
16 OAc 0.62±0.04 0.82±0.07
17 H 0.64±0.06 0.71±0.03
18 H 1.30±0.63 2.64±0.45
19 H 0.60±0.01 0.79±0.10
20 H 0.92±0.56 1.55±0.04
29 H 1.01±0.03 1.20±0.12
30 H 0.82±0.02 0.93±0.21
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R R′ SKBr3 (μM) MCF-7 (μM)
31 H >50 >50
32 H >50 >50
33 H 0.72±0.01 0.99±0.04
a
Values represent mean ± standard deviation for at least two separate experiments performed in triplicate






















Zhao and Blagg Page 15
Table 2
Anti-proliferative activities of NA-2 analogues
R1 R2 SKBr3 (μM) MCF-7 (μM)
KU-407 CH3 CH3 0.44±0.02a 1.35±0.38
35a CH2CH3 H 0.72±0.34 0.98±0.35
35b CH2CH3 CH3 0.73±0.06 2.19±0.50
35c CH2CH3 CH2CH3 4.90±0.42 6.39±0.04
35d CH2CH2CH3 H 0.99±0.03 0.98±0.00
35e CH2CH2CH3 CH2CH2CH3 >50 >50
35f CH2CH(CH3)2 H 1.03±0.02 1.32±0.06
35g CH(CH3)2 H 0.75±0.26 0.74±0.16
35h CH(CH3)2 CH3 0.57±0.13 1.05±0.06
35i CH(CH3)2 CH(CH3)2 1.60±0.02 1.31±0.39
35j C(CH3)3 H 0.66±0.06 0.95±0.10
35k C(CH3)3 CH3 0.88±0.10 1.14±0.11
35l CH2COOMe H 1.06±0.11 2.82±0.27
35m CH2COOH H 7.57±2.86 18.11±5.35
35n CH2CONH2 H 2.29±0.47 1.46±0.35
35o CH2CH2OH H 0.61±0.06 1.56±0.09
a
Values represent mean ± standard deviation for at least two separate experiments performed in triplicate
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Table 3
Anti-proliferative activity of NA-2 derivatives with cyclic N-substitutions
R1 R2 SKBr3 (μM) MCF-7 (μM)
37a Cyclohexyl H 0.66±0.12a 1.07±0.35
37b Cyclohexyl CH3 0.97±0.03 1.08±0.07
37c Phenyl H >50 >50
37d Phenyl CH3 >50 >50
37e Benzyl H 0.47±0.16 0.91±0.01
37f (R)-1-phenylethyl H 1.00±0.31 1.45±0.20
37g Cumenyl H 0.96±0.01 1.07±0.01
37h Benzyl CH3 10.73±0.49 11.52±4.16
37i H 0.77±0.13 1.03±0.12
37j Adamantyl H 0.31±0.04 0.32±0.03
a
Values represent mean ± standard deviation for at least two separate experiments performed in triplicate
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